About

This guide provides supplemental information for the Retacrit Dosing Calculator. It explains the tool's outputs, use cases, and the clinical principles behind its calculations, which are based on the official prescribing information for Retacrit® (epoetin alfa-epbx). This information is for educational purposes and should not replace clinical judgment.

Outputs

The calculator provides two primary types of outputs based on the selected calculation type:

• Initial Dose Calculation: For patients new to therapy, the tool calculates a weight-based starting dose in total units. It specifies the recommended administration frequency (e.g., three times weekly) and route (e.g., subcutaneous or intravenous) based on the clinical indication.
• Dose Adjustment Recommendation: For patients on existing therapy, the tool analyzes the current weekly dose, current hemoglobin (Hb) level, and rate of Hb change to provide a recommendation. This may include increasing the dose, decreasing the dose, or maintaining the current regimen.

How to use

Follow these steps to use the calculator effectively:

1. Select Calculation Type: Choose "Initial Dose Calculation" for new patients or "Dose Adjustment Recommendation" for patients already receiving Retacrit.
2. Select Clinical Indication: Choose the appropriate reason for treatment from the dropdown menu, such as Anemia due to CKD, Chemotherapy, or Surgery.
3. Enter Patient Data: For initial dosing, provide the patient's weight in kilograms or pounds. For dose adjustments, enter the current weekly dose, current hemoglobin, the change in hemoglobin since the last measurement, and the time period over which that change occurred.

Dosing overview

The dosing strategy for Retacrit is individualized based on the patient's condition and response to treatment. The goal is to use the lowest dose sufficient to reduce the need for red blood cell transfusions.

• Anemia due to CKD: The starting dose range is 50 to 100 units/kg three times weekly. The route of administration (IV or SC) depends on whether the patient is on dialysis.
• Anemia due to Chemotherapy: Two main regimens are available: a weight-based dose of 150 units/kg three times per week or a fixed weekly dosing of 40,000 units. Both are administered subcutaneously.
• Perioperative Use (Surgery): To reduce allogeneic blood transfusions, patients may receive 300 units/kg/day for 15 days or 600 units/kg weekly for 4 weeks via subcutaneous injection.

Switching

When switching a patient from another epoetin alfa product to Retacrit, the initial weekly dosing should be the same. Due to potential differences in bioavailability between subcutaneous and intravenous administration, dose adjustments may be necessary to maintain the target hemoglobin level. Monitor patients closely during the transition period.

Missed dose

If a patient misses a scheduled dose, they should contact their healthcare provider for instructions. The missed dose should be administered as soon as possible, and the regular dosing schedule should be resumed. Patients should not take two doses at the same time to make up for a missed one.

Safety alerts

Healthcare providers should be aware of important safety considerations and boxed warnings associated with all Erythropoiesis-Stimulating Agents (ESAs), including Retacrit.

FAQ

Frequently asked questions about the Retacrit dosing calculator and its clinical context.

• Why does the initial dose calculation depend on weight?
  The initial dose is based on clinical trial data that established effective weight-based (units/kg) starting regimens to achieve a target hemoglobin response.
• Why isn't weight needed for a dose adjustment calculation?
  Dose adjustments are based on the patient's individual response (i.e., change in hemoglobin) to their current dose. The focus shifts from the initial weight-based estimate to titrating the existing weekly dosing up or down.
• What is the difference between the two chemotherapy regimens?
  The 150 units/kg 3x/week regimen and the 40,000 units once weekly regimen are two different, approved dosing schedules. The choice may depend on patient convenience, adherence, and clinical preference.
• Why does the calculator recommend reducing the dose if Hb rises by more than 1 g/dL in 2 weeks?
  A rapid increase in hemoglobin can be associated with an increased risk of adverse cardiovascular events. The prescribing information recommends a dose reduction of at least 25% to ensure a more gradual and safe rise in Hb levels.
• How long should I wait before increasing a dose for an inadequate response?
  Dose increases should not be made more frequently than every 4 weeks (or 8 weeks for HIV patients). This allows sufficient time for the red blood cell count to respond to the current dose.
• What should be checked before increasing the dose?
  Before any dose increase, it is critical to evaluate the patient's iron status. Adequate iron stores are necessary for an effective response to Retacrit.
• Can this calculator be used for pediatric patients?
  No. This calculator is designed for adult dosing based on the provided indications. Pediatric dosing requires separate consultation of the full prescribing information.
• Does the calculated dose need to be rounded?
  Yes, the calculated dose should be rounded to the nearest available vial strength to allow for accurate administration and minimize medication waste.

References

This tool is based on established clinical guidelines and prescribing information. For complete details, consult the primary sources.

1. Retacrit® (epoetin alfa-epbx) Prescribing Information. U.S. Food and Drug Administration. Available at: FDA Label for Retacrit
2. Drugs@FDA: FDA-Approved Drugs - Retacrit. U.S. Food and Drug Administration. Available at: Drugs@FDA Database Entry
3. Retacrit (epoetin alfa-epbx) for Healthcare Professionals. Pfizer Inc. Available at: PfizerPro Official Website
4. KDIGO 2012 Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. Kidney Int Suppl. 2012;2(4):279-335.